The Neuroimmunology Laboratory at DMSC receives patient samples to be analysed for biomarkers used for disease diagnosis or analysed for the development of treatment-specific neutralizing antibodies. The clinical analysis includes measurement of IgG oligoclonal bands, neutralizing IFN-beta and Tysabri antibodies, aquaporin-4 antibodies, s-acetylcholine receptor antibodies and neurofilament light chain.
This analysis serves to detect oligoclonal antibodies (IgG) in the CSF. Identification of oligoclonal antibodies in the CSF may be used for diagnosis of MS.
This analysis serves to detect antibodies against aquaporin-4 (NMO-IgG). Identification of autoantibodies against aquaporin-4 may be used for diagnosis of Neuromyelitis Opticus.
This analysis serves to detect antibodies against interferon-beta. Interferon-beta treatment may result in the development of antibodies that neutralize the biological effects of treatment.
This analysis serves to detect antibodies against the acetylcholine receptor. Identification of autoantibodies against the acetylcholine receptor may be used for diagnosis of Myasthenia Gravis.
This analysis serves to detect antibodies against Tysabri (natalizumab). Treatment with Tysabri may result in the development of antibodies that neutralize the biological effects of treatment.
This analysis serves to measure the level of neurofilament light chain in the CSF. An increased level of intrathecal neurofilament light chain may be indicative of neurodegeneration.
+45 38 63 33 84 (office)
+45 38 63 32 03 (laboratory)
Helle.Bach.Soendergaard@regionh.dk (office)
RH-FP-neurolab@regionh.dk (laboratory)